Sinil Pharmaceutical Co. Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.017x

Sinil Pharmaceutical Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, Sinil Pharmaceutical Co. Ltd (012790) has a cash flow conversion efficiency ratio of 0.017x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.62 Billion ≈ $1.78 Million USD) by net assets (₩151.71 Billion ≈ $102.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Sinil Pharmaceutical Co. Ltd (2014–2024)

Cash flow conversion efficiency of Sinil Pharmaceutical Co. Ltd from 2014 to 2024. This chart illustrates how Sinil Pharmaceutical Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Sinil Pharmaceutical Co. Ltd for real-time trading data and today's change.

Sinil Pharmaceutical Co. Ltd Cash Flow Conversion Ratio Explained

Sinil Pharmaceutical Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Sinil Pharmaceutical Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Sinil Pharmaceutical Co. Ltd ranked by their cash flow conversion efficiency. Also see 012790 company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Interlink Electronics Inc NASDAQ:LINK	0.068x
Bewhere Holdings Inc V:BEW	0.009x
Daebongls.Co.Ltd KQ:078140	-0.018x
Connect Biopharma Holdings Ltd NASDAQ:CNTB	-1.189x
PEDEVCO Corp NYSE MKT:PED	0.064x
Cherrybro co.Ltd KQ:066360	0.064x
Shareholder Value Beteiligungen AG XETRA:SVE	0.043x
TNR Gold Corp. V:TNR	-0.126x

Annual Cash Flow Conversion Efficiency for Sinil Pharmaceutical Co. Ltd (2014–2024)

The table below shows the annual cash flow conversion efficiency of Sinil Pharmaceutical Co. Ltd from 2014 to 2024. Review cash generation quality of Sinil Pharmaceutical Co. Ltd to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩146.51 Billion ≈ $99.28 Million	₩22.69 Billion ≈ $15.38 Million	0.155x	+37.85%
2023-12-31	₩134.90 Billion ≈ $91.42 Million	₩15.15 Billion ≈ $10.27 Million	0.112x	+1.18%
2022-12-31	₩123.28 Billion ≈ $83.54 Million	₩13.69 Billion ≈ $9.28 Million	0.111x	+12.59%
2021-12-31	₩113.20 Billion ≈ $76.71 Million	₩11.16 Billion ≈ $7.57 Million	0.099x	-4.18%
2020-12-31	₩107.48 Billion ≈ $72.84 Million	₩11.06 Billion ≈ $7.50 Million	0.103x	-15.33%
2019-12-31	₩101.24 Billion ≈ $68.61 Million	₩12.31 Billion ≈ $8.34 Million	0.122x	+25.83%
2018-12-31	₩95.18 Billion ≈ $64.51 Million	₩9.19 Billion ≈ $6.23 Million	0.097x	+1.27%
2017-12-31	₩90.93 Billion ≈ $61.62 Million	₩8.67 Billion ≈ $5.88 Million	0.095x	-31.23%
2016-12-31	₩87.19 Billion ≈ $59.09 Million	₩12.09 Billion ≈ $8.20 Million	0.139x	+13.38%
2015-12-31	₩78.17 Billion ≈ $52.98 Million	₩9.56 Billion ≈ $6.48 Million	0.122x	-7.08%
2014-12-31	₩70.85 Billion ≈ $48.01 Million	₩9.33 Billion ≈ $6.32 Million	0.132x	--

About Sinil Pharmaceutical Co. Ltd

KQ:012790 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$49.12 Million

₩72.48 Billion KRW

Market Cap Rank

#21782 Global

#1317 in Korea

Share Price

₩6270.00

Change (1 day)

+0.80%

52-Week Range

₩4900.00 - ₩6530.00

All Time High

₩50717.45